Erciyes University initiated to administer the second dose of the novel coronavirus (Covid-19) vaccine candidate within the scope of Phase-2 studies. In this context, the second dose of the inactive vaccine candidate, the Phase 2 studies of which were initiated on February 10, 2021, began to be administered to the volunteers.

Developed against Covid-19 at Erciyes University Vaccine Research and Development Center (ERAGEM) and supported by the Ministry of Health and Health Institutes of Turkey (TUSEB), the second dose of inactive vaccine candidate within the scope of Phase-2 studies was administered to a volunteer at Erciyes University Good Clinical Practice and Research Center (IKUM).

Stating that there were no side effects of the first dose, the volunteer told that he was pleased and proud to attend the vaccine studies and invited everyone to be a volunteer.

Expressing that they are planning to complete the Phase-2 studies in mid-April, our Rector, Prof. Dr. Mustafa Çalış, said: “Phase-2 studies of domestic vaccine supported by the Ministry of Health and Health Institutes of Turkey (TUSEB) and developed at our University are ongoing. Today, the second dose was administered to the volunteer whose first dose was administered in our Phase-2 study. Everything goes very well in our studies we have carried out so far. We hope that Phase-2 studies will proceed as successfully as the Phase-1 studies and that Phase-2 dosing will end in mid-April.”